1.5 Abstract in rivista

1.5 Abstract in rivista: [2363] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.221 a 1.240 di 2.363

The role of sulphate, in hyperomocysteinemia in patients with Helicobacter pylori.

2001 Capodicasa, Enrico; Pelli, Ma; De Medio, Ge; Brunetti, M:

Rottura spontanea del fegato in corso di sindrome di Budd-Chiari da Lupus anticoagulant

2001 Capodicasa, Enrico; Acciarini, Ae; Gerli, Roberto; DEL FAVERO, Albano

Valutazione della capacità sierica scavenger verso il rdicale idrossilico in pazienti emodializzati.

2012 Capodicasa, Enrico; Bottilglieri, L.; Orsi, E.; Standoli, M. L.; De Santis, P.; Scaccetti, A.; Biondi, Roberto

A pilot study with all-trans retinoic acid plus tamoxifen and vitamin E in patients with hepatocellular carcinoma (HCC): a four years follow-up

2002 Clerici, C; Fiorucci, Stefano; Castellani, D; Russo, G; Gentili, G; Morelli, Olivia; Baldoni, Monia

NCX 1000, an NO-derivative of ursodeoxycholic acid protects against Th1-mediated liver damage in mice.

2000 Fiorucci, Stefano; Santucci, L; Mencarelli, A; Morelli, Olivia; Del Soldato, P; Morelli, Antonio

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linforni (IIL).

2008 Chisesi, T; Bellei, M; Luminari, S; Marcheselli, L; Levis, A; Vitolo, U; Stelitano, C; Pavone, V; Merli, F; Liberati, Anna Marina

ABVD versus VEPEMB in elderly Hodgkin's lymphoma patients

2007 Levis, A; Merli, F.; Tamiazzo, S; Arcari, A; Bellei, M; Brugiatelli, M; Federico, M; Liberati, Anna Marina; Et, All

Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients

2009 Gay, F.; Falco, P; Crippa, C; Liberati, Anna Marina; Et, All

A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients

2006 Palumbo, A; Aitoro, G; Bringhen, S.; Caravita, T; Callea, V; Zambello, R; Pregno, P; Carubelli, A; Baraldi, A; Cellini, C; Dore, F; Piro, E; Ambrosini, Mt; Musto, P; Liberati, Anna Marina; Boccadoro, M.

Mobilising chemotherapy affects the recovery of clonogenic peripheral blood stem cells

2006 Schippa, M; Falchi, L.; Rauco, A; Desantis, G; Merluzzi, M; Ferrara, P; Lugini, A; Liberati, Anna Marina

Antitumour activity of bortezomib-pegylated liposomal doxorubicine association: Results of an ongoing study in multiple myeloma patients.

2006 Braccalenti, G.; Ferrara, P; Gubbiotti, M; Cerroni, P; Emili, R; Morandi, Mg; Pace, R; Liberati, Anna Marina

Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial.

2006 Ladetto, M; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All

Impact of early consolidation with bortezomib, thalidomide and dexamethasone on molecularly-detectable disease in MM patients in CR or VGPR following autologous transplantation: Uncommon achievement of molecular remission despite evidence of tumor load reduction by real time PCR.

2006 Ladetto, M; Astolfi, M; Santo, L; Avonto, I; Cavallo, F; Pagliano, G; Pregno, P; Grasso, M; Liberati, Anna Marina

Philadelphia chromosome (Ph') secondary clones in chronic myeloid leukemia (CML) are not indicative of resistance to IFNa- or imatinib-based treatment regimens.

2006 Falchi, L; Prontera, P; Luzi, D; Festuccia, V; Emili, R; Gottardi, E; Donti, E; Liberati, Anna Marina

Persistent molecular remission in patients treated with imatinib-IFNa combination or imatinib monotherapy

2006 Schippa, M; Gottardi, E; Luzi, D; Falchi, L; Emili, R; Angeletti, I; Desantis, G; Gentileschi, E; Cerroni, P; Liberati, Anna Marina

Patterns of clonal evolution in Ph'-positive chronic myelogenous leukemia (CML) during chronic phase: Overall incidence, type, multiplicity, development time, effect on subsequent genetic instability, sokal risk, type of bcr/abl transcript and hematological evolution.

2006 Luzi, D; Falchi, L; Emili, R; Angeletti, I; Prontera, P; Venti, G; Bassetti, A; Gubbiotti, M; Capparella, V; Gentileschi, E; Donti, E; Liberati, Anna Marina

Rituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as first line treatment in stage III-IV diffuse large B-Cell lymphoma (DLBCL) at poor prognosis: Final analysis of phase II GIMURELL trial.

2006 Vitolo, U; Cabras, Mg; Rossi, G; Liberati, Anna Marina

A prospective, randomized, phase III study of melphalan 200 mg/m(2) (MEL200) versus melphalan 100 mg/m(2) (MEL100) in newly diagnosed myeloma patients.

2006 Palumbo, A; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina

Impact of complete kariotypic remission (CKR) and sokal risk on overall survival in chronic myelogenous leukemia (CML) patients: A monocentric experience.

2006 Falchi, L; Schippa, M; Luzi, D; Emili, R; Festuccia, V; Giugliano, E; Ardisia, C; Rauco, A; Pace, R; Doriti, E; Liberati, Anna Marina

Clinical and molecular results of the multicenter randomized GITMO-IIL, trial in poor risk follicular lymphoma (FL) at diagnosis: Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS.

2006 Ladetto, M; de Marco, F; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All

Titolo	Data di pubblicazione	Autore(i)
The role of sulphate, in hyperomocysteinemia in patients with Helicobacter pylori.	2001	Capodicasa, Enrico; Pelli, Ma; De Medio, Ge; Brunetti, M:
Rottura spontanea del fegato in corso di sindrome di Budd-Chiari da Lupus anticoagulant	2001	Capodicasa, Enrico; Acciarini, Ae; Gerli, Roberto; DEL FAVERO, Albano
Valutazione della capacità sierica scavenger verso il rdicale idrossilico in pazienti emodializzati.	2012	Capodicasa, Enrico; Bottilglieri, L.; Orsi, E.; Standoli, M. L.; De Santis, P.; Scaccetti, A.; Biondi, Roberto
A pilot study with all-trans retinoic acid plus tamoxifen and vitamin E in patients with hepatocellular carcinoma (HCC): a four years follow-up	2002	Clerici, C; Fiorucci, Stefano; Castellani, D; Russo, G; Gentili, G; Morelli, Olivia; Baldoni, Monia
NCX 1000, an NO-derivative of ursodeoxycholic acid protects against Th1-mediated liver damage in mice.	2000	Fiorucci, Stefano; Santucci, L; Mencarelli, A; Morelli, Olivia; Del Soldato, P; Morelli, Antonio
Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linforni (IIL).	2008	Chisesi, T; Bellei, M; Luminari, S; Marcheselli, L; Levis, A; Vitolo, U; Stelitano, C; Pavone, V; Merli, F; Liberati, Anna Marina
ABVD versus VEPEMB in elderly Hodgkin's lymphoma patients	2007	Levis, A; Merli, F.; Tamiazzo, S; Arcari, A; Bellei, M; Brugiatelli, M; Federico, M; Liberati, Anna Marina; Et, All
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients	2009	Gay, F.; Falco, P; Crippa, C; Liberati, Anna Marina; Et, All
A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients	2006	Palumbo, A; Aitoro, G; Bringhen, S.; Caravita, T; Callea, V; Zambello, R; Pregno, P; Carubelli, A; Baraldi, A; Cellini, C; Dore, F; Piro, E; Ambrosini, Mt; Musto, P; Liberati, Anna Marina; Boccadoro, M.
Mobilising chemotherapy affects the recovery of clonogenic peripheral blood stem cells	2006	Schippa, M; Falchi, L.; Rauco, A; Desantis, G; Merluzzi, M; Ferrara, P; Lugini, A; Liberati, Anna Marina
Antitumour activity of bortezomib-pegylated liposomal doxorubicine association: Results of an ongoing study in multiple myeloma patients.	2006	Braccalenti, G.; Ferrara, P; Gubbiotti, M; Cerroni, P; Emili, R; Morandi, Mg; Pace, R; Liberati, Anna Marina
Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial.	2006	Ladetto, M; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All
Impact of early consolidation with bortezomib, thalidomide and dexamethasone on molecularly-detectable disease in MM patients in CR or VGPR following autologous transplantation: Uncommon achievement of molecular remission despite evidence of tumor load reduction by real time PCR.	2006	Ladetto, M; Astolfi, M; Santo, L; Avonto, I; Cavallo, F; Pagliano, G; Pregno, P; Grasso, M; Liberati, Anna Marina
Philadelphia chromosome (Ph') secondary clones in chronic myeloid leukemia (CML) are not indicative of resistance to IFNa- or imatinib-based treatment regimens.	2006	Falchi, L; Prontera, P; Luzi, D; Festuccia, V; Emili, R; Gottardi, E; Donti, E; Liberati, Anna Marina
Persistent molecular remission in patients treated with imatinib-IFNa combination or imatinib monotherapy	2006	Schippa, M; Gottardi, E; Luzi, D; Falchi, L; Emili, R; Angeletti, I; Desantis, G; Gentileschi, E; Cerroni, P; Liberati, Anna Marina
Patterns of clonal evolution in Ph'-positive chronic myelogenous leukemia (CML) during chronic phase: Overall incidence, type, multiplicity, development time, effect on subsequent genetic instability, sokal risk, type of bcr/abl transcript and hematological evolution.	2006	Luzi, D; Falchi, L; Emili, R; Angeletti, I; Prontera, P; Venti, G; Bassetti, A; Gubbiotti, M; Capparella, V; Gentileschi, E; Donti, E; Liberati, Anna Marina
Rituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as first line treatment in stage III-IV diffuse large B-Cell lymphoma (DLBCL) at poor prognosis: Final analysis of phase II GIMURELL trial.	2006	Vitolo, U; Cabras, Mg; Rossi, G; Liberati, Anna Marina
A prospective, randomized, phase III study of melphalan 200 mg/m(2) (MEL200) versus melphalan 100 mg/m(2) (MEL100) in newly diagnosed myeloma patients.	2006	Palumbo, A; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina
Impact of complete kariotypic remission (CKR) and sokal risk on overall survival in chronic myelogenous leukemia (CML) patients: A monocentric experience.	2006	Falchi, L; Schippa, M; Luzi, D; Emili, R; Festuccia, V; Giugliano, E; Ardisia, C; Rauco, A; Pace, R; Doriti, E; Liberati, Anna Marina
Clinical and molecular results of the multicenter randomized GITMO-IIL, trial in poor risk follicular lymphoma (FL) at diagnosis: Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS.	2006	Ladetto, M; de Marco, F; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.221 a 1.240 di 2.363

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2363

IRIS - Res&Arch Institutional Research Information System - Research & Archive